The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.75
Bid: 24.00
Ask: 25.50
Change: -0.25 (-1.00%)
Spread: 1.50 (6.25%)
Open: 25.00
High: 25.00
Low: 24.75
Prev. Close: 25.00
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Statement re. Suspension

9 Jul 2008 15:45

RNS Number : 7132Y
Sareum Holdings PLC
09 July 2008
 



9 July 2008

Sareum Holdings plc ("Sareum" or "the Company")

Suspension of trading of Sareum shares on AIM

On 19 June 2008, the Company announced that the board of Sareum ("the Board") believed that the Company needed to undertake a strategic transaction and that should the Board decide within a short timescale that a strategic transaction is not achievable, the Board would take a decision as to the future of the Company in its present form, as the Company would not be able to continue operations without a significant fundraising.

Since 19 June, the Board has continued to progress discussions with a number of parties, including in respect of a possible reverse transaction, but at this time does not consider that it will be able to conclude a strategic transaction for several months.  Further, in the current difficult financial markets, the Board does not consider that it will be possible to achieve a significant fundraising to enable the Company to continue operations in its present form although the Board may still need to secure interim funding to enable it to complete a strategic transaction.

In view of the uncertainty that the Company will be able to raise funds or complete a strategic transaction, the Board has requested a suspension of trading in its shares on AIM.

Contacts:

 

Sareum Holdings plc

01223 497700

Tim Mitchell, Chief Executive Officer

 

Buchanan Communications

020 7466 5000

Tim Anderson, Mary-Jane Johnson 

 

Grant Thornton UK LLP

020 7383 5100

Philip Secrett, Colin Aaronson

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
SRSSSEFLUSASEEW
Date   Source Headline
7th May 20242:10 pmRNSExercise of Warrants
23rd Apr 20247:00 amRNSFinal Issue of RiverFort Subscription Shares
19th Apr 202411:35 amRNSIssue of RiverFort Subscription Shares
15th Apr 20243:28 pmRNSIssue of RiverFort Subscription Shares
9th Apr 20244:00 pmRNSIssue of RiverFort Subscription Shares
4th Apr 20242:38 pmRNSCompletion of Equity Fundraise
2nd Apr 20244:51 pmRNSResult of WRAP Retail Offer
2nd Apr 20247:00 amRNSIncrease in size of WRAP Retail Offer
28th Mar 20247:02 amRNSWRAP Retail Offer
28th Mar 20247:01 amRNSEquity Fundraise
28th Mar 20247:00 amRNSSareum Half-Year Report
15th Mar 20247:00 amRNSNew Patent Allowance
12th Mar 20241:30 pmRNSNotice of Interim Results and Trading Update
15th Feb 20247:00 amRNSUpdate on SDC-1801 Clinical Trial Progress
2nd Jan 20247:00 amRNSDevelopment and commercialisation licence SRA737
14th Dec 20233:35 pmRNSResults of AGM
14th Dec 20237:00 amRNSAnnual General Meeting Statement
23rd Nov 20237:00 amRNSDrawdown of Equity Prepayment Facility
21st Nov 20237:00 amRNSNotice of AGM, Annual Report and Accounts
9th Nov 20237:00 amRNSInitiation of food effects study for SDC-1801
8th Nov 20233:03 pmRNSDirector Dealings
3rd Nov 20237:05 amRNSSareum enhances SDC-1801 patent protection
2nd Nov 20232:48 pmRNSExercise of Share Options and Director Dealings
9th Oct 20237:00 amRNSFinal Results for the Year Ended 30 June 2023
3rd Oct 20237:00 amRNSNotice of Results and Investor Presentation
6th Sep 20237:00 amRNSDirector's Dealing
5th Sep 20237:00 amRNSDirector Dealing
4th Sep 20237:00 amRNSDosing of first subjects in MAD Phase 1a trial
16th Aug 20237:00 amRNSUpdate on financial and operational progress
3rd Aug 20237:00 amRNSEquity Prepayment Facility of up to £5 million
26th Jun 20237:00 amRNSSareum Announces Two New Granted Patents
6th Jun 20237:00 amRNSDosing commences in Phase 1a trial of SDC-801
18th May 20237:00 amRNSPhase 1a clinical trial for SDC-1801
5th May 20239:20 amRNSApproval to initiate Phase 1 clinical trial
22nd Mar 20237:00 amRNSHalf-Year Report
15th Mar 20237:01 amRNSUpdate on SDC-1801
15th Mar 20237:00 amRNSNotice of Half-Year Results
6th Mar 20237:00 amRNSUpdate on SRA737
29th Dec 20223:14 pmRNSDirector/PDMR Shareholding
16th Dec 20223:29 pmRNSResults of AGM
16th Dec 20227:00 amRNSAGM Statement
24th Nov 20227:00 amRNSNotice of AGM, Annual Report and Accounts
21st Nov 20227:00 amRNSSareum notes publication of SRA737 clinical data
9th Nov 20224:41 pmRNSSecond Price Monitoring Extn
9th Nov 20224:35 pmRNSPrice Monitoring Extension
9th Nov 20222:05 pmRNSSecond Price Monitoring Extn
9th Nov 20222:00 pmRNSPrice Monitoring Extension
9th Nov 202211:05 amRNSSecond Price Monitoring Extn
9th Nov 202211:00 amRNSPrice Monitoring Extension
9th Nov 20229:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.